Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,765 across all filing types
Latest filing 2023-01-25 Investor Presentation
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Presentation to analysts on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2022
Investor Presentation Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding a presentation to analysts on unaudited consolidated financial results for the quarter and nine months ended 31st December 2022. It includes summary revenue data for Q3 FY23 compared to Q3 FY22. The document is relatively short (1823 characters) and explicitly states it is a presentation to analysts on quarterly financial results. This matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. It is not the full quarterly report (IR) nor an earnings release (ER) since it is a presentation to analysts. Therefore, the correct classification is Investor Presentation (IP).
2023-01-25 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding a presentation to analysts on unaudited consolidated financial results for the quarter and nine months ended 31st December 2022. It includes summary revenue data for Q3 FY 2022-23. The document is relatively short (1823 characters) and explicitly states it is a presentation to analysts on quarterly financial results. This matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. It is not a full quarterly report (IR) because it is a presentation, not a comprehensive report with full financial statements. It is not an earnings release (ER) because it is a presentation document, not just key highlights. Therefore, the correct classification is Investor Presentation (IP).
2023-01-25 English
Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Capital/Financing Update Classification · 90% confidence The document is a letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements. It announces the approval of audited standalone financial results and unaudited consolidated financial results for the quarter and nine months ended 31st December 2022, along with the audit and limited review reports. It also mentions a press release on financial results and an interim dividend declaration. The document is short (2184 characters) and primarily serves as an announcement of the financial results and dividend, not the full financial report itself. Therefore, it is best classified as a Capital/Financing Update (CAP) due to the dividend announcement and financial results update, rather than a full Interim/Quarterly Report (IR) or Earnings Release (ER).
2023-01-25 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a detailed filing from Torrent Pharmaceuticals Limited dated 25th January 2023. It includes an auditor's report on the standalone quarterly financial results for the quarter and nine months ended 31 December 2022. The report references compliance with SEBI Listing Regulations and Indian Accounting Standards, and contains detailed financial data including revenue, expenses, and profit figures. The presence of an independent auditor's opinion, detailed financial statements, and management responsibilities indicates this is a formal financial report rather than a brief announcement or press release. The document is comprehensive and contains substantive financial data and analysis for an interim period (quarter and nine months), which fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or certification, so it is not classified as RPA or RNS. Therefore, the appropriate classification is IR with high confidence.
2023-01-25 English
Date of payment of dividend
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI Listing Obligations, indicating an intimation about financial results and dividend declaration. It mentions approval of audited standalone financial results and unaudited consolidated financial results for the quarter and nine months ended 31st December 2022, along with audit and limited review reports. It also announces an interim dividend. The document is short (2184 characters) and serves as an announcement of the financial results and dividend, not the full financial report itself. Therefore, it is best classified as a Capital/Financing Update (CAP) because it includes dividend declaration and financial results announcement but does not contain the full detailed financial statements or analysis typical of an Interim/Quarterly Report (IR).
2023-01-25 English
Dividend Updates
Earnings Release Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements. It announces the approval of audited standalone financial results and unaudited consolidated financial results for the quarter and nine months ended 31st December 2022, along with the audit and limited review reports. It also mentions an interim dividend declaration. The document includes a press release on financial results and states that the financial results will be published on the company's website. The document length is 2184 characters, which is relatively short and primarily serves as an announcement of the financial results and dividend, not the full financial report itself. Therefore, according to the MENU VS MEAL rule, this is an announcement of financial results and dividend, not the full report. The best fitting category is Earnings Release (ER), which covers initial announcements of quarterly/periodical financial results and key highlights, including dividend declarations.
2023-01-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.